Curated News
By: NewsRamp Editorial Staff
April 29, 2025
HeartBeam's 3D ECG Technology Achieves Major Milestone in Clinical Study
TLDR
- HeartBeam's 3D ECG technology achieved 93.4% diagnostic agreement, providing a competitive edge in arrhythmia assessment.
- HeartBeam's synthesized 12-lead ECG technology aims to deliver hospital-grade cardiac insights via a credit card-sized device, enhancing patient care.
- HeartBeam's innovative ECG technology revolutionizes cardiac care, empowering patients with actionable heart intelligence outside medical facilities.
- HeartBeam's cable-free 12-lead ECG captures heart signals in 3D, redefining the future of cardiac health management with portable devices.
Impact - Why it Matters
This news highlights the groundbreaking success of HeartBeam's innovative 3D ECG technology, which could revolutionize cardiac care by enabling portable, cable-free 12-lead ECGs for patients outside medical facilities. The high diagnostic agreement with standard ECGs is a significant step towards bringing advanced cardiac insights directly to patients, potentially transforming how cardiac health is managed and diagnosed.
Summary
HeartBeam (NASDAQ: BEAT) revealed that its synthesized 12-lead ECG technology successfully met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Dr. Thomas Deering presented the results during the Heart Rhythm Society's annual conference. The company's 3D ECG technology, designed for a credit card-sized device, aims to provide hospital-grade cardiac insights to patients anywhere, with commercialization planned post-FDA clearance.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, HeartBeam's 3D ECG Technology Achieves Major Milestone in Clinical Study
